Who
Michael S. Perry
Director
Company insider
Files Form 4 as: Director, Arrowhead Pharmaceuticals; Chief Executive Officer, Avita Medical; Director, Armata Pharmaceuticals; President & CMO, Poniard Pharmaceuticals.
In numbers
- Trades disclosed
- 96
- Buys
- 3
- Sells
- 19
- Bought
- $200K
- Sold
- $14.2M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 8 May 2006
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.0M11,600 at $87.30 | filing |
| 18 Aug 2026filed 20 Aug 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.0M11,600 at $87.30 | filing |
| 16 Dec 2025filed 18 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,819 at $0.00 | filing |
| 5 Dec 2025filed 9 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $992K16,250 at $61.03 | filing |
| 18 Dec 2024filed 20 Dec 2024 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $385K16,733 at $22.99 | filing |
| 15 Dec 2023filed 19 Dec 2023 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $381K14,987 at $25.41 | filing |
| 10 Jan 2023filed 11 Jan 2023 | ARWR Arrowhead Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,593 at $0.00 | filing |
| 10 Jan 2023filed 11 Jan 2023 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,867 at $0.00 | filing |
| 21 Nov 2022filed 22 Nov 2022 | RCEL Avita Medicaloption or derivative · Medical Devices | SEC FORM 4 Code M | —150,000 at $0.00 | filing |
| 21 Nov 2022filed 22 Nov 2022 | RCEL Avita MedicalMedical Devices | SEC FORM 4 Code M | $899K150,000 at $5.99 | filing |
| 21 Nov 2022filed 22 Nov 2022 | RCEL Avita MedicalMedical Devices | SEC FORM 4 Sold | $1.1M150,000 at $7.18 | filing |
| 1 Sep 2022filed 6 Sep 2022 | RCEL Avita Medicaloption or derivative · Medical Devices | SEC FORM 4 Code A | —3,450 at $0.00 | filing |
| 1 Sep 2022filed 6 Sep 2022 | RCEL Avita MedicalMedical Devices | SEC FORM 4 Code A | —2,980 at $0.00 | filing |
| 1 Jun 2022filed 2 Jun 2022 | RCEL Avita MedicalMedical Devices | SEC FORM 4 Code J | —23,754 at $0.00 | filing |
| 24 Feb 2022filed 25 Feb 2022 | RCEL Avita MedicalMedical Devices | SEC FORM 4 Sold | $94K10,812 at $8.74 | filing |
| 23 Feb 2022filed 25 Feb 2022 | RCEL Avita Medicaloption or derivative · Medical Devices | SEC FORM 4 Code A | —3,450 at $0.00 | filing |
| 23 Feb 2022filed 25 Feb 2022 | RCEL Avita MedicalMedical Devices | SEC FORM 4 Code A | —23,753 at $0.00 | filing |
| 23 Feb 2022filed 25 Feb 2022 | RCEL Avita MedicalMedical Devices | SEC FORM 4 Code A | —5,960 at $0.00 | filing |
| 7 Jan 2022filed 7 Jan 2022 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,400 at $0.00 | filing |
| 3 Jan 2022filed 4 Jan 2022 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $169K2,628 at $64.30 | filing |
News
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and CRISPR Therapeutics (NASDAQ:CRSP) Financial ReviewARWR · themarketsdaily.com · 26 Oct 2026Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)ARWR · dailypolitical.com · 21 Oct 2026Arrowhead Pharmaceuticals' (ARWR) Buy Rating Reiterated at Chardan CapitalARWR · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Michael S. Perry; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.